Elephas is committed to helping pharmaceutical and biotechnology researchers accelerate immunotherapy drug development with a breakthrough approach for assessing response to investigational agents.
Powered by our Cybrid™ platform, our technology suite is the only solution based on live tumor fragments (LTF)™ with the native tumor architecture and immune cells intact.
With Cybrid™ we can generate an array of outputs, including secretome profiling, cellular markers, transcriptome analysis, and advanced 3D imaging.
RAPID RESULTS, ACTIONABLE DATA SETS
Within two weeks of the study start date, we can offer data and visualization of the impact of your agent on a tumor and its immune cells.* This rapid turnaround provides insights and understanding of the agent’s potential impact on patients. Results are delivered through seamless and frictionless exports of full data sets through our secure cloud-based portal, CybridView™.
*<20 patient samples, time from receipt of test article
COLLABORATION AND COOPERATION
Elephas will support your studies from initial design through final data readouts. Along with the wealth of data our technology suite will provide, your team will have direct access to our expert cancer biologists and analysts. This unique connection is vital in setting our partners ahead of competitors and ensuring the highest probability of success for assets.